Ausgabe 9/2023
Inhalt (20 Artikel)
The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
Enrique Montero, Jeffrey S. Isenberg
A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma
Hong-My Nguyen, Mariam Oladejo, Wyatt Paulishak, Laurence M. Wood
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
Jordi Pfeifer Serrahima, Congcong Zhang, Pranav Oberoi, Malena Bodden, Jasmin Röder, Claudia Arndt, Anja Feldmann, Anne Kiefer, Maren Prüfer, Ines Kühnel, Torsten Tonn, Michael Bachmann, Winfried S. Wels
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia
Ji Yoon Lee, Soojin Park, A-Reum Han, Hee-Sun Hwang, Hee-Je Kim
Murine regulatory T cells utilize granzyme B to promote tumor metastasis
Ellis Tibbs, Rakhee Rathnam Kalari Kandy, Delong Jiao, Long Wu, Xuefang Cao
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
Joshua F. Meckler, Daniel J. Levis, Daniel P. Vang, Joseph M. Tuscano
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
Chengpei Zhu, Hu Li, Xiaobo Yang, Shanshan Wang, Yunchao Wang, Nan Zhang, Yanyu Wang, Jingnan Xue, Longhao Zhang, Cong Ning, Xu Yang, Ziyu Xun, Jiashuo Chao, Junyu Long, Xinting Sang, Zhenyu Zhu, Haitao Zhao
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W. Myint, Thomas Büttner, Hideki Takeshita, Yohei Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Küronya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, Robert Kemp, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina-Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer
Mizuki Haraguchi, Kazuma Kiyotani, Tomohiro Tate, Seiji Sakata, Ray Sagawa, Satoshi Takagi, Satoshi Nagayama, Kengo Takeuchi, Kazuhisa Takahashi, Ryohei Katayama
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)
Yuankai Shi, Jie Cui, Hui Zhou, Xiaohong Zhang, Liqun Zou, Junning Cao, Yuhuan Gao, Chuan Jin, Xiaoling Li, Hui Liu, Zhigang Peng, Liping Xie, Huilai Zhang, Weihua Zhang, Hongyu Zhang, Liye Zhong, Fang Zhou, Genny Guo, Wenduo He
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
Hampartsoum B. Barsoumian, Kewen He, Ethan Hsu, Genevieve Bertolet, Duygu Sezen, Yun Hu, Thomas S. Riad, Maria Angelica Cortez, James W. Welsh
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
Colt A. Egelston, Weihua Guo, Susan E. Yost, Xuan Ge, Jin Sun Lee, Paul H. Frankel, Yujie Cui, Christopher Ruel, Daniel Schmolze, Mireya Murga, Aileen Tang, Norma Martinez, Misagh Karimi, George Somlo, Peter P. Lee, James R. Waisman, Yuan Yuan
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents
Claire Battin, Annika De Sousa Linhares, Judith Leitner, Anna Grossmann, Daniela Lupinek, Shiva Izadi, Alexandra Castilho, Petra Waidhofer-Söllner, Katharina Grabmeier-Pfistershammer, Jochen Stritzker, Peter Steinberger
IL-36α inhibits melanoma by inducing pro-inflammatory polarization of macrophages
Xinyi Lou, Shixin Duan, Mengkai Li, Yao Yuan, Shiyi Chen, Zhiming Wang, Zishu Wang, Lei Sun, Feng Qian
Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains
Marjolein C. Stip, J. H. Marco Jansen, Maaike Nederend, Maria Tsioumpekou, Mitchell Evers, Patricia A. Olofsen, Friederike Meyer-Wentrup, Jeanette H. W. Leusen
TGF-β1 mediates tumor immunosuppression aggravating at the late stage post-high-light-dose photodynamic therapy
Lingfei Han, Xiaoxian Huang, Bin Zhao, Hongtan Zhu, Ruyi Wang, Shaoxia Liu, Honglei Lin, Feng Feng, Xiao Ma, Fulei Liu, Jingwei Xue, Wenyuan Liu
The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity
Carlo Girone, Federica Calati, Irene Lo Cigno, Valentina Salvi, Valentina Tassinari, Tiziana Schioppa, Cinzia Borgogna, Ludovica Lospinoso Severini, John Hiscott, Cristina Cerboni, Alessandra Soriani, Daniela Bosisio, Marisa Gariglio
Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy
Ludwig O. Pachmayr, Anton Muehlbauer, Sophie Flommersfeld, Franziska Graml, Julian Hoenninger, Louisa von Baumgarten, Veit R. Buchholz, Simon Grassmann
Tumor immunology meets oncology (TIMO) XVI, July 07–09 2022 in Halle/Saale, Germany
Barbara Seliger
Considerations regarding the tumor-suppressor role of naringenin as a novel agent for the treatment of oral squamous cell carcinoma
Chen-xi Li, Zhong-cheng Gong, Xiao-rong Tan